Amarin Corporation PLC (AMRN) - Net Assets
Based on the latest financial reports, Amarin Corporation PLC (AMRN) has net assets worth $459.28 Million USD as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($670.77 Million) and total liabilities ($211.49 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Amarin Corporation PLC (AMRN) liquid assets ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $459.28 Million |
| % of Total Assets | 68.47% |
| Annual Growth Rate | 10.6% |
| 5-Year Change | -31.15% |
| 10-Year Change | N/A |
| Growth Volatility | 151.42 |
Amarin Corporation PLC - Net Assets Trend (1993–2025)
This chart illustrates how Amarin Corporation PLC's net assets have evolved over time, based on quarterly financial data. Also explore Amarin Corporation PLC total assets for the complete picture of this company's asset base.
Annual Net Assets for Amarin Corporation PLC (1993–2025)
The table below shows the annual net assets of Amarin Corporation PLC from 1993 to 2025. For live valuation and market cap data, see AMRN market cap.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $459.28 Million | -5.53% |
| 2024-12-31 | $486.18 Million | -11.94% |
| 2023-12-31 | $552.10 Million | -7.26% |
| 2022-12-31 | $595.33 Million | -10.76% |
| 2021-12-31 | $667.10 Million | +6.31% |
| 2020-12-31 | $627.50 Million | +3.16% |
| 2019-12-31 | $608.26 Million | +299.31% |
| 2018-12-31 | $152.33 Million | +333.99% |
| 2017-12-31 | $-65.10 Million | -618.70% |
| 2016-12-31 | $-9.06 Million | +92.99% |
| 2015-12-31 | $-129.19 Million | -46.06% |
| 2014-12-31 | $-88.45 Million | -161.25% |
| 2013-12-31 | $-33.86 Million | -747.04% |
| 2012-12-31 | $-4.00 Million | +32.96% |
| 2011-12-31 | $-5.96 Million | +97.05% |
| 2010-12-31 | $-202.37 Million | -516.38% |
| 2009-12-31 | $48.60 Million | +68.18% |
| 2008-12-31 | $28.90 Million | +19.67% |
| 2007-12-31 | $24.15 Million | -36.17% |
| 2006-12-31 | $37.84 Million | -1.93% |
| 2005-12-31 | $38.58 Million | +131.11% |
| 2004-12-31 | $16.69 Million | +362.96% |
| 2003-12-31 | $-6.35 Million | -2.16% |
| 2002-12-31 | $-6.21 Million | -120.95% |
| 2001-12-31 | $29.67 Million | -4.82% |
| 2000-12-31 | $31.17 Million | +155.88% |
| 1999-12-31 | $12.18 Million | +190.23% |
| 1998-12-31 | $-13.50 Million | -191.84% |
| 1997-12-31 | $14.70 Million | -36.91% |
| 1996-12-31 | $23.30 Million | -19.38% |
| 1995-12-31 | $28.90 Million | +57.92% |
| 1993-12-31 | $18.30 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Amarin Corporation PLC's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 170634400000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $310.18 Million | 67.54% |
| Other Components | $1.86 Billion | 404.21% |
| Total Equity | $459.28 Million | 100.00% |
Amarin Corporation PLC Competitors by Market Cap
The table below lists competitors of Amarin Corporation PLC ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Bali Towerindo Sentra Tbk
JK:BALI
|
$292.80 Million |
|
LEXINFINTECH ADR/2 CL.A
F:1LFA
|
$292.98 Million |
|
Lafayette Digital Acquisition Corp. I Class A Ordinary Shares
NASDAQ:ZKP
|
$293.03 Million |
|
SolGold PLC
TO:SOLG
|
$293.08 Million |
|
FSP Technology Inc
TW:3015
|
$292.63 Million |
|
Zhihu Inc ADR
NYSE:ZH
|
$292.52 Million |
|
Crescent Biopharma, Inc.
NASDAQ:CBIO
|
$292.50 Million |
|
Coltene Holding AG
SW:CLTN
|
$292.50 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Amarin Corporation PLC's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 486,176,000 to 459,281,000, a change of -26,895,000 (-5.5%).
- Net loss of 38,798,000 reduced equity.
- Other factors increased equity by 11,903,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-38.80 Million | -8.45% |
| Other Changes | $11.90 Million | +2.59% |
| Total Change | $- | -5.53% |
Book Value vs Market Value Analysis
This analysis compares Amarin Corporation PLC's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 12.71x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has increased from 0.00x to 12.71x over the analyzed period, suggesting growing market confidence.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 1993-12-31 | $3253.33 | $14.07 | x |
| 1995-12-31 | $4370.84 | $14.07 | x |
| 1996-12-31 | $3286.32 | $14.07 | x |
| 1997-12-31 | $1985.68 | $14.07 | x |
| 1998-12-31 | $-1800.00 | $14.07 | x |
| 1999-12-31 | $1624.78 | $14.07 | x |
| 2000-12-31 | $740.29 | $14.07 | x |
| 2001-12-31 | $141.75 | $14.07 | x |
| 2002-12-31 | $-133.10 | $14.07 | x |
| 2003-12-31 | $-74.20 | $14.07 | x |
| 2004-12-31 | $120.42 | $14.07 | x |
| 2005-12-31 | $190.94 | $14.07 | x |
| 2006-12-31 | $94.21 | $14.07 | x |
| 2007-12-31 | $51.55 | $14.07 | x |
| 2008-12-31 | $1.31 | $14.07 | x |
| 2009-12-31 | $22.91 | $14.07 | x |
| 2010-12-31 | $-40.38 | $14.07 | x |
| 2011-12-31 | $-0.92 | $14.07 | x |
| 2012-12-31 | $-0.56 | $14.07 | x |
| 2013-12-31 | $-4.05 | $14.07 | x |
| 2014-12-31 | $-10.18 | $14.07 | x |
| 2015-12-31 | $-0.72 | $14.07 | x |
| 2016-12-31 | $-0.86 | $14.07 | x |
| 2017-12-31 | $-4.81 | $14.07 | x |
| 2018-12-31 | $10.25 | $14.07 | x |
| 2019-12-31 | $35.52 | $14.07 | x |
| 2020-12-31 | $32.87 | $14.07 | x |
| 2021-12-31 | $33.15 | $14.07 | x |
| 2022-12-31 | $29.68 | $14.07 | x |
| 2023-12-31 | $27.09 | $14.07 | x |
| 2024-12-31 | $23.66 | $14.07 | x |
| 2025-12-31 | $1.11 | $14.07 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Amarin Corporation PLC utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -8.45%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -21.23%
- • Asset Turnover: 0.27x
- • Equity Multiplier: 1.46x
- Recent ROE (-8.45%) is above the historical average (-20.70%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 1993 | 4.92% | 6.12% | 0.61x | 1.32x | $-930.00K |
| 1995 | 14.19% | 14.09% | 0.82x | 1.23x | $1.21 Million |
| 1996 | -66.95% | -72.56% | 0.48x | 1.93x | $-17.93 Million |
| 1997 | -52.38% | -31.69% | 0.60x | 2.73x | $-9.17 Million |
| 1998 | 0.00% | -288.00% | 0.61x | 0.00x | $-27.45 Million |
| 1999 | 35.88% | 38.96% | 0.33x | 2.77x | $3.15 Million |
| 2000 | 8.15% | 16.15% | 0.32x | 1.56x | $-575.90K |
| 2001 | -16.05% | -95.33% | 0.05x | 3.07x | $-7.73 Million |
| 2002 | 0.00% | -56.61% | 0.67x | 0.00x | $-36.46 Million |
| 2003 | 0.00% | -261.02% | 0.16x | 0.00x | $-18.59 Million |
| 2004 | 19.34% | 317.50% | 0.04x | 1.42x | $1.56 Million |
| 2005 | -53.26% | -4109.40% | 0.01x | 1.21x | $-24.41 Million |
| 2006 | -71.15% | -5384.00% | 0.01x | 1.29x | $-30.70 Million |
| 2007 | -158.05% | -518.22% | 0.17x | 1.75x | $-40.58 Million |
| 2008 | -69.28% | 0.00% | 0.00x | 1.27x | $-22.91 Million |
| 2009 | -122.05% | 0.00% | 0.00x | 1.16x | $-64.18 Million |
| 2010 | 0.00% | 0.00% | 0.00x | 0.00x | $-229.28 Million |
| 2011 | 0.00% | 0.00% | 0.00x | 0.00x | $-68.83 Million |
| 2012 | 0.00% | 0.00% | 0.00x | 0.00x | $-178.78 Million |
| 2013 | 0.00% | -630.82% | 0.10x | 0.00x | $-162.84 Million |
| 2014 | 0.00% | -103.99% | 0.32x | 0.00x | $-47.52 Million |
| 2015 | 0.00% | -140.91% | 0.47x | 0.00x | $-102.28 Million |
| 2016 | 0.00% | -66.38% | 0.78x | 0.00x | $-85.44 Million |
| 2017 | 0.00% | -37.47% | 1.12x | 0.00x | $-61.35 Million |
| 2018 | -76.44% | -50.80% | 0.59x | 2.53x | $-131.68 Million |
| 2019 | -3.72% | -5.27% | 0.49x | 1.45x | $-83.47 Million |
| 2020 | -2.87% | -2.93% | 0.64x | 1.54x | $-80.75 Million |
| 2021 | 1.16% | 1.33% | 0.55x | 1.60x | $-58.98 Million |
| 2022 | -17.77% | -28.66% | 0.42x | 1.49x | $-165.34 Million |
| 2023 | -10.71% | -19.26% | 0.37x | 1.51x | $-114.32 Million |
| 2024 | -16.90% | -35.95% | 0.33x | 1.41x | $-130.80 Million |
| 2025 | -8.45% | -21.23% | 0.27x | 1.46x | $-84.73 Million |
Industry Comparison
This section compares Amarin Corporation PLC's net assets metrics with peer companies in the Drug Manufacturers - General industry.
Industry Context
- Industry: Drug Manufacturers - General
- Average net assets among peers: $18,692,339,444
- Average return on equity (ROE) among peers: 34.76%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Amarin Corporation PLC (AMRN) | $459.28 Million | 4.92% | 0.46x | $292.71 Million |
| AbbVie Inc (ABBV) | $4.49 Billion | 91.90% | 5.50x | $365.30 Billion |
| Amgen Inc (AMGN) | $25.78 Billion | 20.01% | 1.68x | $177.77 Billion |
| AstraZeneca PLC (AZN) | $23.95 Billion | 26.05% | 1.24x | $286.40 Billion |
| Biogen Inc (BIIB) | $5.81 Billion | 13.49% | 0.46x | $27.45 Billion |
| Bristol-Myers Squibb Company (BMY) | $12.21 Billion | 42.98% | 1.42x | $118.52 Billion |
| Gilead Sciences Inc (GILD) | $1.87 Billion | 24.02% | 0.15x | $163.34 Billion |
| GlaxoSmithKline PLC ADR (GSK) | $8.32 Billion | 55.33% | 3.74x | $111.15 Billion |
| Johnson & Johnson (JNJ) | $70.42 Billion | 23.49% | 1.01x | $547.37 Billion |
| Eli Lilly and Company (LLY) | $15.39 Billion | 15.53% | 1.36x | $862.20 Billion |
About Amarin Corporation PLC
Amarin Corporation plc, a pharmaceutical company, engages in the commercialization and development of therapeutics for the treatment of cardiovascular diseases in the United States, Europe, and internationally. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia. … Read more